Mij
Senior Member (Voting Rights)
These findings provide further evidence that there might be a correlation between the length of time the virus stays in the body and the risk of long COVID (appendix p 1). Therefore, rapid viral elimination in patients with persistent SARS-CoV-2 virus could be crucial. We summarised the approved and ongoing, but unpublished, randomised trials on the nirmatrelvir with ritonavir (a SARS-CoV-2 main protease inhibitor) treatment for long COVID (appendix p 3) or persistence of SARS-CoV-2 in post-COVID-19 patients (appendix p 4) listed on ClinicalTrials.gov. The results of a recent observational study on nirmatrelvir with ritonavir and long COVID are promising and intriguing, and demand further investigation. The use of nirmatrelvir with ritonavir might eliminate viral reservoirs and alleviate long COVID symptoms.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00142-X/fulltext
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00142-X/fulltext